A molecular docking study of the newly synthesized quinoxaline derivatives at the histone deacetylase (HDAC) receptor was performed, and the co-crystallized inhibitor, trichostatin A (TSA), was used as a reference standard. Using MOE 2019.0102 drug design software (Inc, 2016 ), the binding mode of the compound against histone deacetylase (ID: 1C3R) was predicted (Finnin et al., 1999 (link)). The crystal structure of the target receptor (HDAC) was downloaded from Protein Data Bank (http://www.rcsb.org/ , PDB code: 1C3R, resolution of 2.00 Å) (Finnin et al., 1999 (link)). The protein structure was prepared for docking studies by the default method (Alnajjar et al., 2020 (link); Soltan et al., 2021 (link); Soltane et al., 2021 (link); Zaki et al., 2020 (link)). The deacetylase and deacetylase-TSA structures show an active site consisting of a tubular pocket, a zinc-binding site (which is the metal cofactor required for HDAC activity), and two Asp-His charge-relay systems, and explain the mechanism of HDAC inhibition (Finnin et al., 1999 (link)). Validation of the docking procedure was carried out by applying the docking process for the co-crystallized ligand (Elmaaty et al., 2021a (link); Elmaaty et al., 2021b (link); Kandeil et al., 2021 (link)). All of the newly synthesized quinoxaline derivatives were prepared and imported in the same database together with the co-crystallized inhibitor (TSA) and generally docked. After completion of the docking process, the obtained poses for each were carefully studied, and the ones having the best scores and binding modes with the protein pocket residues were selected.
Full text: Click here